Trump keeps Francis Collins as NIH Director

Francis Collins, MD, PhD, will remain director of the National Institutes of Health (NIH), making him one of the few appointees of President Barack Obama to stay on in the Trump administration.

“I consider it a privilege to continue to lead this noble enterprise,” Collins tweeted after the announcement.

There had been calls for President Donald Trump to replace Collins, who has served as NIH Director since 2009. A group of 40 congressmen, led by Rep. Jim Banks, R-Indiana, cited Collins’ support for embryonic stem cell research in a May letter as a reason for dismissal. He's also faced criticism for safety issues at NIH facilities under his watch, including mold being found in a NIH pharmacy and the 2015 closure of a sterile production unit. Other Republicans, however, commended Trump’s decision to retain him.

“This is good news for the country and one of President Trump’s best appointments. There’s nobody better qualified than Francis Collins to help accelerate the medical miracles that have the potential to help virtually every American family,” Sen. Lamar Alexander, R-Tennessee, said in a statement. Alexander had endorsed the idea of keeping Collins after Trump was elected.

Sen. Roy Blunt, R-Missouri, also applauded the move, saying in his own statement he would “look forward to working with him to ensure NIH has the resources it needs to advance progress toward new, life-saving treatments and cures.”

Resources could be the next big battle for Collins at NIH, as Trump’s proposed budget would cut its funding by 18 percent, or $5.8 billion. This would include a $1.2 billion cut for the National Cancer Institute and a $672 million reduction for the National Heart, Lung and Blood Institute, along with limiting with NIH grant recipients can spend on administrative costs related to their research.

The reductions may be opposed by some of the same Republicans who have supported Collins’s reappointment. When Congress passed a spending deal for the final five months of the current fiscal year, it included an extra $2 billion in funding for NIH.

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.